Open Access
Ann Toxicol Anal
Volume 25, Numéro 2, 2013
Page(s) 47 - 56
Publié en ligne 17 septembre 2013
  1. Perrin M, Lecompte Y, Roussel O, Le Boisselier R, Bourgine J, Coquerel A. Nouvelles drogues. In : Kintz P (coordinateur). Traité de toxicologie médico-judiciaire. Paris : Elsevier 2012: 507–547. [Google Scholar]
  2. Coppola M, Mondola R. Synthetic cathinones: Chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as “bath salts” or “plant food”. Toxicol Lett. 2012; 211: 144–149. [CrossRef] [PubMed] [Google Scholar]
  3. Mugele J, Nañagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use : a case report. Ann Emerg Med. 2012; 60(1) : 100–102. [CrossRef] [PubMed] [Google Scholar]
  4. Máté F, Csaba F. Dizájner drog indukálta pszichózis. Neuropsychopharmacologia Hungarica. 2012; 14(2) : 137–140 (Hungarian). [Google Scholar]
  5. Thornton SL, Gerona RR, Tomaszewski CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol. 2012; 8(3) : 310–313. [CrossRef] [PubMed] [Google Scholar]
  6. Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol. 2012; 68(5) : 853–856. [CrossRef] [PubMed] [Google Scholar]
  7. Turcant A, Premel-Cabic A, Cailleux A, Allain P. Toxicological screening of drugs by microbore high-performance liquid chromatography with photodiode-array detection and ultraviolet spectral library searches. Clin Chem. 1991; 37: 1210–1215. [PubMed] [Google Scholar]
  8. Gruson A et groupe «accréditation» SFTA. Aide à la validation des méthodes en toxicologie et suivi thérapeutique pharmacologique. Ann Toxicol Anal. 2005; S1: 1–20. [Google Scholar]
  9. Westphal F, Junge T, Rösner P, Sönnichsen F, Schuster F. Mass and NMR spectroscopic characterization of 3,4 methylenedioxypyrovalerone : a designer drug with α-pyrrolidinophenone structure. Forensic Sci Int. 2009; 190: 1–8. [CrossRef] [PubMed] [Google Scholar]
  10. Hays PA, Casale JF, Berrier AL. The characterization of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine). Microgram J. 2012; 9(1) : 3–17. [Google Scholar]
  11. Ojanperä IA, Heikman PK, Rasanen IJ. Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther Drug Monit. 2011; 33(2) : 257–263. [PubMed] [Google Scholar]
  12. Kriikku P, Wilhelm L, Schwarz O, Rintatalo J. New designer drug of abuse : 3,4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int. 2011; 210(1–3) : 195–200. [CrossRef] [Google Scholar]
  13. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts” containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol. 2012; 8: 69–75. [CrossRef] [PubMed] [Google Scholar]
  14. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-methylene dioxypyrovalerone. Ann Emerg Med. 2012; 60: 103–105. [CrossRef] [PubMed] [Google Scholar]
  15. Meyer MR, Du P, Schuster F, Maurer HH. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom. 2010; 45(12) : 1426–1442. [CrossRef] [PubMed] [Google Scholar]
  16. Shields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS. Methoxetamine associated reversible cerebellar toxicity : three cases with analytical confirmation. Clin Toxicol. 2012; 50: 438–440. [Google Scholar]
  17. Ferec S, Lelièvre B, Diquet B, Leborgne I, Harry P, Turcant A. Dosages plasmatique et urinaire de 3,4-méthylènedioxypyrovalérone et de méthoxétamine par CLHP-UV-BD et CLHP-SM/SM : à propos d’un cas. Ann Toxicol Anal. 2012; S1: 17–18. [Google Scholar]
  18. Boucher A, Gaulier JM, Delhome G, Cueto T, Boudinaud M, Maublanc J, Dulaurent S, Imbert L, Descotes J, Lachâtre G. Aspects cliniques et analytiques d’une intoxication par la méthoxétamine. Ann Toxicol Anal. 2012; S1: 13–14. [Google Scholar]
  19. Abe E, Ricard F, Duverneuil-Mayer C, Knapp A, Grassin-Delyle S, Darrouzain F, Alvarez JC. Non letal intoxication with methoxetamine, a novel ketamine-like drug. Ann Toxicol Anal. 2012; S1: 22. [Google Scholar]
  20. Abe E, Ricard F, Darrouzain F, Alvarez JC. An automated method for measurement of methoxetamine in human plasma by use of turbulent flow on-line extraction coupled with liquid chromatography and mass spectrometric detection. Anal Bioanal Chem. 2013; 405: 239–245. [CrossRef] [PubMed] [Google Scholar]
  21. Sein Anand J, Wiergowski M, Barwina M, Kaletha K. Accidental intoxication with high dose methoxetamine (MXE) – a case report. Przegl Lek. 2012; 69: 609–610. [PubMed] [Google Scholar]
  22. Wikström M, Thelander G, Dahlgren M, Kronstrand R. An accidental fatal intoxication with methoxetamine. J Anal Toxicol. 2013; 37: 43–46. [CrossRef] [PubMed] [Google Scholar]
  23. Meyer MR, Bach M, Bovens M, Turcant A, Maurer HH. Methoxetamine : metabolism and detectability of a novel ketamine analog – studied by GC-MS, LC-MSn, and LC-HR-MSn. GTFCh congress Mosbach April 2013. [Google Scholar]
  24. Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH. Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Anal Bioanal Chem. 24 : 2013; 405(19) : 6307–6321. [CrossRef] [PubMed] [Google Scholar]
  25. Hofer KE, Grager B, Müller DM, Rauber-Lüthy C, Kupferschmidt H, Rentsch KM, Ceschi A. Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med. 2012; 60: 97–99. [CrossRef] [PubMed] [Google Scholar]